Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feifei Teng

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Clinical Lung Cancer|October 21, 2018
Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the PrognosisXiangjiao Meng, Yongsheng Gao, Lian Yang, et al.
Frontiers in Oncology|February 28, 2022
Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung AdenocarcinomaXinge Li, Jie Wang, Xu Chang, et al.
Neuro-Oncology|April 6, 2017
MR-guided radiation therapy: transformative technology and its role in the central nervous systemYue Cao, Chia-Lin Tseng, James M Balter, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|July 26, 2015
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancerFeifei Teng, Xiangjiao Meng, Li Kong, et al.
Future Oncology (London, England)|August 20, 2019
The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancerDuoying Wang, Dong Guo, Fang Shi, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|October 16, 2024
Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefitsFeifei Teng, Xiao Ju, Zhenhua Gao, et al.
American Journal of Cancer Research|August 14, 2015
Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancerFeifei Teng, Dianbin Mu, Xiangjiao Meng, et al.
Frontiers in Immunology|September 12, 2025
Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysisJunhao Xu, Jinquan Yao, Yuxin Geng, et al.
Oncotarget|September 8, 2016
Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisionsFeifei Teng, Xiangjiao Meng, Xin Wang, et al.
Molecular Carcinogenesis|January 21, 2025
Computed Tomography-Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non-Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and ImmunotherapyYuxin Geng, Tianwen Yin, Yikun Li, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Clinical Lung Cancer|October 21, 2018
Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the PrognosisXiangjiao Meng, Yongsheng Gao, Lian Yang, et al.
Frontiers in Oncology|February 28, 2022
Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung AdenocarcinomaXinge Li, Jie Wang, Xu Chang, et al.
Neuro-Oncology|April 6, 2017
MR-guided radiation therapy: transformative technology and its role in the central nervous systemYue Cao, Chia-Lin Tseng, James M Balter, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|July 26, 2015
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancerFeifei Teng, Xiangjiao Meng, Li Kong, et al.
Future Oncology (London, England)|August 20, 2019
The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancerDuoying Wang, Dong Guo, Fang Shi, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|October 16, 2024
Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefitsFeifei Teng, Xiao Ju, Zhenhua Gao, et al.
American Journal of Cancer Research|August 14, 2015
Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancerFeifei Teng, Dianbin Mu, Xiangjiao Meng, et al.
Frontiers in Immunology|September 12, 2025
Neoadjuvant immunotherapy plus chemotherapy for resectable non-small cell lung cancer with driver mutations: a retrospective analysisJunhao Xu, Jinquan Yao, Yuxin Geng, et al.
Oncotarget|September 8, 2016
Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisionsFeifei Teng, Xiangjiao Meng, Xin Wang, et al.
Molecular Carcinogenesis|January 21, 2025
Computed Tomography-Based Radiomics and Genomics Analyses for Survival Prediction of Stage III Unresectable Non-Small Cell Lung Cancer Treated With Definitive Chemoradiotherapy and ImmunotherapyYuxin Geng, Tianwen Yin, Yikun Li, et al.
Pageof 6